EC looks to CureVac for first mRNA COVID-19 vaccine deal

The European Commission is nearing a procurement deal for CureVac’s COVID-19 mRNA-based vaccine, which would add mechanistic diversity of the portfolio of vaccines it is pursuing. The EU has secured doses of an adenovirus vector vaccine and is in talks for a second vaccine in the class, as well as a recombinant protein-based vaccine.

Separately, J&J’s Phase III vaccine trial could enroll twice as many volunteers as pivotal studies of three other candidates, and a therapy from CalciMedica shows promise in severe COVID-19 patients...